Enterprise
Samsung Bioepis has begun direct sales of the low-concentration formulation(40 mg/ml) of its ophthalmic disease treatment, OPUVIZ, in Europe. Samsung Bioepis announced that it is targeting a global market worth approximately KRW 12 trillion in annual sales with OPUVIZ, a biosimilar of ‘Eylea’ developed by the U.S. company Regeneron.
![LG그룹[T01] [NSPAD]LG그룹](https://file.nspna.com/ad/T01_lgfuture_5298.gif)
![삼성전자[T01] [NSPAD]삼성전자](https://file.nspna.com/ad/T01_samsung_5043.gif)